Abstract
Studies of patients scheduled for percutaneous coronary intervention with acute coronary syndrome have shown that the addition of intravenous glycoprotein (GP) IIb/IIIa inhibitors to aspirin and heparin is associated with a reduction in death or myocardial infarction compared to therapy with aspirin and heparin alone. The principle safety issue with GP IIb/IIIa inhibitors is the risk of bleeding, as the potent antiplatelet effect of these drugs may adversely affect hemostasis. In addition, antagonists of GP IIb/IIIa may increase the risk of thrombocytopenia. We report a case of abciximab-induced severe thrombocytopenia which led to fatal intra-cranial hemorrhage.
MeSH terms
-
Abciximab
-
Aged
-
Angioplasty, Balloon, Coronary / methods
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Combined Modality Therapy
-
Coronary Angiography
-
Coronary Stenosis / diagnostic imaging
-
Coronary Stenosis / therapy*
-
Fatal Outcome
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage
-
Immunoglobulin Fab Fragments / adverse effects*
-
Infusions, Intravenous
-
Intracranial Hemorrhages / chemically induced*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects*
-
Severity of Illness Index
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Abciximab